The week of 2025-12-29, 10 holders filed a new Schedule 13D and 35 a new Schedule 13G reporting 5% or more of a company, and 0 13D filings stated in Item 4 an intent to influence the company. Open a company for every holder and the purpose each 13D states, quoted.
New Schedule 13D
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2025-12-31 | BMP AI Technologies, Inc. | Vighnesh Harinarayan Dobale | 67.59% | SCHEDULE 13D |
| 2025-12-31 | Energy Focus, Inc. | Huang Chiao Chieh | 31.9% | SCHEDULE 13D |
| 2025-12-29 | Churchill Capital Corp XI | Churchill Sponsor XI LLC | 25.67% | SCHEDULE 13D |
| 2026-01-02 | Rocky Mountain Chocolate Factory, Inc. | ARM-D Rocky Mountain Chocolate Holdings LLC | 16.1% | SCHEDULE 13D |
| 2025-12-31 | CISO Global, Inc. | Hensley & Company IRS# 86-0255475 | 14.82% | SCHEDULE 13D |
| 2025-12-29 | Elite Health Systems Inc. | jeereddi Prasad Anjaneya | 12.7% | SCHEDULE 13D |
| 2025-12-30 | Cloopen Group Holding Limited | TB Alternative Assets Ltd. | 12.19% | SCHEDULE 13D |
| 2026-01-02 | In8bio, Inc. | Emily Fairbairn | 7.5% | SCHEDULE 13D |
| 2025-12-29 | Chicago Rivet & Machine Co | Galloway Capital Partners, LLC | 6.45% | SCHEDULE 13D |
| 2025-12-29 | Myomo, Inc. | Horton Capital Partners, LLC | 5.1% | SCHEDULE 13D |
New Schedule 13G
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2025-12-29 | Minerva Neurosciences, Inc. | Federated Hermes, Inc. | 19.86% | SCHEDULE 13G |
| 2026-01-02 | Zura Bio Limited | Athanor Capital | 15.7% | SCHEDULE 13G |
| 2025-12-29 | Medline Inc. | GIC Private Limited | 14.64% | SCHEDULE 13G |
| 2025-12-29 | Andersen Group Inc. | Durable Capital Partners LP | 13.2% | SCHEDULE 13G |
| 2025-12-29 | GRI Bio, Inc. | Lincoln Alternative Strategies LLC | 11.83% | SCHEDULE 13G |
| 2025-12-30 | Shf Holdings, Inc. | M3 Funds, LLC | 10% | SCHEDULE 13G |
| 2025-12-29 | Minerva Neurosciences, Inc. | Dapice Joshua J. | 9.99% | SCHEDULE 13G |
| 2025-12-29 | Actelis Networks, Inc. | S.H.N. Financial Investments Ltd. | 9.99% | SCHEDULE 13G |
| 2025-12-31 | VisionWave Holdings, Inc. | Blade Ranger Ltd. | 9.99% | SCHEDULE 13G |
| 2025-12-31 | Minerva Neurosciences, Inc. | Vivo Opportunity Fund Holdings, L.P. | 9.99% | SCHEDULE 13G |
| 2026-01-02 | SOBR Safe, Inc. | Mitchell P. Kopin | 9.99% | SCHEDULE 13G |
| 2026-01-02 | Marti Technologies, Inc. | DLD Asset Management, LP | 9.99% | SCHEDULE 13G |
| 2025-12-29 | Nyxoah SA | CVI Investments, Inc. | 9.9% | SCHEDULE 13G |
| 2025-12-30 | Robo.ai Inc. | JAK Mobility Ventures II LLC | 9.9% | SCHEDULE 13G |
| 2025-12-30 | Safe & Green Holdings Corp. | JAK Industrial Ventures I LLC | 9.9% | SCHEDULE 13G |
| 2025-12-31 | Tonix Pharmaceuticals Holding Corp. | Point72 Asset Management, L.P. | 9.2% | SCHEDULE 13G |
| 2025-12-31 | Polestar Automotive Holding UK PLC | Banco Bilbao Vizcaya Argentaria S.A. | 8.4% | SCHEDULE 13G |
| 2025-12-30 | In8bio, Inc. | 683 Capital Management, LLC | 7.86% | SCHEDULE 13G |
| 2025-12-29 | Powercompute, Inc. | Mitchell P. Kopin | 7.6% | SCHEDULE 13G |
| 2025-12-30 | Dermata Therapeutics, Inc. | Bigger Michael | 7.43% | SCHEDULE 13G |
| 2025-12-31 | Sidus Space Inc | CVI Investments, Inc. | 7.4% | SCHEDULE 13G |
| 2025-12-30 | Zentalis Pharmaceuticals, Inc. | Andrew J. Schwab | 6.4% | SCHEDULE 13G |
| 2025-12-29 | TGE Value Creative Solutions Corp. | Millennium Management LLC | 6% | SCHEDULE 13G |
| 2025-12-30 | Chewy, Inc. | Viking Global Investors LP | 5.7% | SCHEDULE 13G |
| 2025-12-29 | Sweetgreen, Inc. | Woodson Capital Management, LP | 5.63% | SCHEDULE 13G |
| 2026-01-02 | Dermata Therapeutics, Inc. | Mitchell P. Kopin | 5.5% | SCHEDULE 13G |
| 2025-12-29 | Eventbrite, Inc. | Glazer Capital, LLC | 5.31% | SCHEDULE 13G |
| 2025-12-29 | Century Casinos Inc | Veradace Partners LP | 5.3% | SCHEDULE 13G |
| 2025-12-31 | Silicon Valley Acquisition Corp. | Millennium Management LLC | 5.3% | SCHEDULE 13G |
| 2025-12-29 | AlTi Global, Inc. | Islet Management, LP | 5.27% | SCHEDULE 13G |
| 2025-12-29 | Smart Share Global Limited | Glazer Capital, LLC | 5.22% | SCHEDULE 13G |
| 2025-12-31 | Hello Group Inc | Athos Capital Ltd | 5.2% | SCHEDULE 13G |
| 2025-12-31 | SEACOR Marine Holdings Inc. | Chernett Jorey | 5.2% | SCHEDULE 13G |
| 2025-12-31 | Inhibikase Therapeutics, Inc. | Trails Edge Capital Partners, LP | 5.1% | SCHEDULE 13G |
| 2025-12-31 | LB Pharmaceuticals Inc. | Trails Edge Capital Partners, LP | 5% | SCHEDULE 13G |
Stated intent
No 13D this week stated an intent to influence the company.
Tools for this story
Each opens in a new tab. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.